Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 18

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 18
---
 The Solicitation” and is incorporated by reference herein. Mr. Mangless’ nominees were elected at the 2023 Annual Meeting, replacing three incumbent directors, including Richard Pascoe, our then Chief Executive Officer. Summaries of our subsequent communications with Mr. Mangless and certain related matters are set forth below.

On May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a director of Zevra at that time, notified the Board that they did not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders. Mr. Plooster and Mr. Saluri informed the Board that they intended to resign as soon as the Board found candidates to fill the vacancies their resignations would create.

On May 5, 2023, Richard W. Pascoe resigned as the Company’s Chief Executive Officer, effective as of June 1, 2023.

On May 13, 2023, the Board appointed Christal M. M. Mickle, Zevra’s then Chief Development Officer, as Zevra’s interim President and Chief Executive Officer and designated Ms. Mickle as Zevra’s principal executive officer. Ms. Mickle is the co-founder of KemPharm, Inc., the predecessor of Zevra, and Dr. Travis Mickle’s ex-wife. In February 2023, the Company changed its name to Zevra Therapeutics, Inc. to reflect the Company’s intensified focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options.

On August 7, 2023, Thomas D. Anderson was appointed to the Board, following a recommendation from the Nominating and Corporate Governance Committee and after being initially identified through a third-party search firm. On the same day, Matthew R. Plooster resigned from his position as a director, as he had previously indicated he would do.

On October 10, 2023, Neil F. McFarlane, who was identified through a third-party search firm, joined Zevra as the Company’s President, Chief Executive Officer, and a director, replacing Ms. Mickle as principal executive officer. Ms. Mickle continued to

<div align='center'>20</div>

serve in her role as Chief Development Officer. On the same day, Joseph B. Saluri resigned from his position as a director, as he had previously indicated he would do.

On October 12, 2023,